[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
April 27, 2005

Arthritis Medications and Cardiovascular Events

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;293(16):1975-1977. doi:10.1001/jama.293.16.1975-b

To the Editor: The Editorial by Dr Topol on the cardiovascular effects of coxibs1 provides new evidence of the ongoing state of confusion involving patients, physicians, and health authorities. The available scientific data, far from clarifying the matter, add to the confusion. An example is the premature cessation of the Alzheimer Disease Anti-inflammatory Prevention Trial (ADAPT) due to an excess of cardiovascular events in the patients treated with naproxen, a nonselective nonsteroidal anti-inflammatory drug (NSAID) previously associated with a reduction in the risk of myocardial infarction.2

First Page Preview View Large
First page PDF preview
First page PDF preview